comparemela.com

Latest Breaking News On - Silvan tuerkcan - Page 6 : comparemela.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The growth-focused money manager is making moves.

Cathie woodSilvan tuerkcanDavid lebowitzTeladoc healthArk investIntellia therapeuticsFull self driving

Crispr Therapeutics AG (CRSP) Receives a Buy from SVB Securities

In a report released on November 11, Mani Foroohar from SVB Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP - Research Report)..

Matthew porteusMani forooharDaniel andersonSecuritiess silvan tuerkcanRodger novakEmmanuelle charpentierShaun patrick foyAlnylam pharmaRocket pharmaceuticalsCrispr therapeuticsSilvan tuerkcanChad cowanCraig mellow

MacroGenics (MGNX) Q3 2022 Earnings Call Transcript

MGNX earnings call for the period ending September 30, 2022.

Jessica huiCharles zhu guggenheimLukas shumwaySilvan tuerkcanCharles zhuJonathan changScott koenigJames karrelsDavid daiFinsight corporationVice presidentChief financialPrivate securities litigation reform actRisk factorsChief executivePrevention bio

Harvard University s Latest Portfolio: 5 Best Biotech Stock Picks

In this article, we will look at Harvard University s latest stock portfolio and list its 5 best biotech stock picks.

Silvan tuerkcanRobert burnsHarvard management companyRelay therapeutics incHarvard universityHarvard university latest portfolioNumber of hedge fund holdersHarvard managementLatest portfolioBiotech stockStake valueHedge fund holdersRelay therapeutics

Crispr Therapeutics Advances 366 Spots To 120th Most Popular With Retail Investors

Crispr Therapeutics AG (NASDAQ:CRSP) is a Swiss-American gene editing biotech company developing gene-based medicines

United statesHenry singletonSilvan tuerkcanBenjamin burnettChardan researchCrispr therapeuticsFull henry singleton seriesPhuong khanh morrowChief medical officerVice presidentGlobal therapeutic area headBrokers think of crispr therapeuticsInnovation day

vimarsana © 2020. All Rights Reserved.